Rare Cancer News & Clinical Trials » Trial

Trial - Adrenal Cancer (26 unread)

Perioperative Residual Adrenal Function After Extended Resection for Retroperitoneal Soft Tissue Sarcomas

Posted: January 13th, 2020, 3:00pm GMT

Conditions: Adrenal; Functional Disturbance; Retroperitoneal Sarcoma; Intraoperative Hypotension
Intervention:
Sponsor: Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
Recruiting
Patients With ES-SCLC and ECOG PS=2 Receiving Atezolizumab-Carboplatin-Etoposide

Posted: January 8th, 2020, 3:00pm GMT

Condition: SCLC, Extensive Stage
Intervention: Drug: Atezolizumab
Sponsors: AIO-Studien-gGmbH; Hoffmann-La Roche
Recruiting
Biological Effect of Vitamin D in Patients With Urothelial Carcinoma

Posted: December 12th, 2019, 3:00pm GMT

Condition: Urothelial Carcinoma
Intervention: Drug: Vitamin D
Sponsors: Germans Trias i Pujol Hospital; Spanish Clinical Research Network - CAIBER; Centro Nacional de Investigaciones Oncologicas CARLOS III; Fundació Institut Germans Trias i Pujol
Not yet recruiting
Virtual Human Delivered Nutrition Module for Colorectal Cancer Prevention

Posted: December 10th, 2019, 3:00pm GMT

Condition: Colorectal Cancer
Interventions: Other: virtual technology - high interactive; Other: virtual technology - low interactive; Other: non-colorectal cancer related module
Sponsors: University of Florida; National Cancer Institute (NCI)
Not yet recruiting
The Effect of Ultrasound Guided Superficial, Deep Serratus Plane Blocks and Thoracic Epidural in Thoracotomy

Posted: December 6th, 2019, 3:00pm GMT

Condition: Post-thoracotomy Pain Syndrome
Intervention: Procedure: Thoracic epidural analgesia , superficial serratus plane block and deep serratus plane block
Sponsor: National Cancer Institute, Egypt
Recruiting
A Novel Therapeutic Vaccine (EO2401) in Metastatic Adrenocortical Carcinoma, or Malignant Pheochromocytoma/Paraganglioma

Posted: December 5th, 2019, 3:00pm GMT

Conditions: Adrenocortical Carcinoma; Pheochromocytoma; Paraganglioma
Intervention: Biological: EO2401
Sponsor: Enterome
Not yet recruiting
RCT of Gastric ESD With or Without Epineprhine Added Solution

Posted: July 25th, 2019, 2:00pm GMT

Conditions: Gastric Neoplasm; Early Gastric Cancer
Interventions: Procedure: Endoscopic submucosal dissection; Drug: Epinephrine
Sponsors: Chinese University of Hong Kong; Osaka International Cancer Institute; Shizuoka Cancer Center; Fukuoka University; Changi General Hospital; Kyoto 2nd Red Cross Hospital; Ishikawa Prefectural Central Hospital; Kosin University Gospel Hospital
Recruiting
Preoperative Regional Nerve Block for Acute and Chronic Post-Operative Pain Following Mastectomy

Posted: July 15th, 2019, 2:00pm GMT

Conditions: Breast Cancer; Mastectomy; Anesthesia, Local; Narcotic Use
Interventions: Drug: regional nerve block with local anesthesia of bupivacaine with steroid; Other: Placebo regional nerveblock with normal saline
Sponsor: University of Alabama at Birmingham
Not yet recruiting
A Study of ASP1951 in Subjects With Advanced Solid Tumors

Posted: January 10th, 2019, 3:00pm GMT

Condition: Advanced Solid Tumors
Interventions: Drug: ASP1951; Drug: pembrolizumab
Sponsor: Astellas Pharma Global Development, Inc.
Recruiting
Conventional ADT w/ or w/Out Abiraterone Acetate + Prednisone and Apalutamide Following a Detectable PSA After Radiation and ADT

Posted: December 18th, 2018, 3:00pm GMT

Condition: Prostate Cancer
Interventions: Drug: Prednisone; Drug: Apalutamide; Drug: Abiraterone Acetate; Drug: LHRH Agonist or Antagonist
Sponsors: Dana-Farber Cancer Institute; Janssen Scientific Affairs, LLC
Recruiting
Long-term Safety and Efficacy Extension Study for Participants With Advanced Tumors Who Are Currently on Treatment or in Follow-up in a Pembrolizumab (MK-3475) Study (MK-3475-587/KEYNOTE-587)

Posted: April 3rd, 2018, 2:00pm GMT

Condition: Solid Tumors
Interventions: Biological: Pembrolizumab; Drug: Standard of Care (SOC)
Sponsor: Merck Sharp & Dohme Corp.
Recruiting
Clinical and Molecular Characteristics of Primary Aldosteronism in Blacks

Posted: December 15th, 2017, 3:00pm GMT

Conditions: Adrenal Gland Neoplasm; Hypertension; Bone Diseases, Metabolic; Cardiovascular Disease; Hyperinsulinemia
Intervention:
Sponsors: National Human Genome Research Institute (NHGRI); Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
Recruiting
Fecal Microbiota Transplantation in Depression

Posted: September 13th, 2017, 2:00pm GMT

Condition: Major Depressive Disorder
Interventions: Drug: Fecal microbiota capsules; Drug: Placebo oral capsule
Sponsor: Psychiatric Hospital of the University of Basel
Recruiting
Over-the-scope Clips and Standard Treatments in Endoscopic Control of Acute Bleeding From Non-variceal Upper GI Causes

Posted: July 13th, 2017, 2:00pm GMT

Conditions: Acute Upper Gastrointestinal Bleeding; Tumor Bleeding
Interventions: Device: Over-the-scope Clips; Device: Hemo-clipping; Device: thermo-coagulation; Drug: Epinephrine
Sponsors: Chinese University of Hong Kong; Queen Mary Hospital, Hong Kong; The First Affiliated Hospital of Soochow University; Beijing Friendship Hospital; Zhejiang University; Ningbo No. 1 Hospital
Recruiting
Lu-177-DOTATATE (Lutathera) in Therapy of Inoperable Pheochromocytoma/ Paraganglioma

Posted: July 2nd, 2017, 2:00pm GMT

Conditions: Pheochromocytoma; Paraganglioma; Neuroendocrine Tumors; Neuroendocrine Neoplasms
Interventions: Drug: Lu-177-DOTATATE; Drug: Ga-68-DOTATATE; Drug: F-18-FDG; Drug: Amino Acid solution
Sponsor: National Cancer Institute (NCI)
Recruiting
A Phase II Trial of the DNA Methyl Transferase Inhibitor, Guadecitabine (SGI-110), in Children and Adults With Wild Type GIST,Pheochromocytoma and Paraganglioma Associated With Succinate Dehydrogenase Deficiency and HLRCC-associated Kidney Cancer

Posted: May 24th, 2017, 2:00pm GMT

Conditions: Paraganglioma; Gastrointestinal Stromal Tumors; Carcinoma, Renal Cell; Renal Neoplasms; Pheochromocytoma
Intervention: Drug: SGI-110 (guadecitabine)
Sponsor: National Cancer Institute (NCI)
Recruiting
Nivolumab in Treating Patients With Localized Kidney Cancer Undergoing Nephrectomy

Posted: February 16th, 2017, 3:00pm GMT

Conditions: Metastatic Malignant Neoplasm in Lymph Node; Metastatic Malignant Neoplasm in the Adrenal Gland; Metastatic Malignant Neoplasm in the Lung; Metastatic Malignant Neoplasm in the Pancreas; Metastatic Malignant Neoplasm in the Skin; Metastatic Malignant Neoplasm in the Soft Tissues; Metastatic Renal Cell Carcinoma; Sarcomatoid Renal Cell Carcinoma; Stage II Renal Cell Cancer AJCC v7; Stage III Renal Cell Cancer AJCC v7; Unclassified Renal Cell Carcinoma
Interventions: Procedure: Conventional Surgery; Biological: Nivolumab; Other: Patient Observation; Other: Quality-of-Life Assessment; Other: Questionnaire Administration
Sponsors: National Cancer Institute (NCI); Canadian Cancer Trials Group
Recruiting
$Permalink for 'Cabozantinib-S-Malate in Treating Younger Patients With Recurrent, Refractory, or Newly Diagnosed Sarcomas, Wilms Tumor, or Other Rare Tumors'$
Cabozantinib-S-Malate in Treating Younger Patients With Recurrent, Refractory, or Newly Diagnosed Sarcomas, Wilms Tumor, or Other Rare Tumors

Posted: August 16th, 2016, 2:00pm GMT

Conditions: Adrenal Cortex Carcinoma; Alveolar Soft Part Sarcoma; Central Nervous System Neoplasm; Childhood Clear Cell Sarcoma of Soft Parts; Clear Cell Sarcoma of Soft Tissue; Ewing Sarcoma; Hepatoblastoma; Hepatocellular Carcinoma; Osteosarcoma; Recurrent Adrenal Cortex Carcinoma; Recurrent Alveolar Soft Part Sarcoma; Recurrent Ewing Sarcoma; Recurrent Hepatoblastoma; Recurrent Hepatocellular Carcinoma; Recurrent Malignant Central Nervous System Neoplasm; Recurrent Malignant Solid Neoplasm; Recurrent Osteosarcoma; Recurrent Renal Cell Carcinoma; Recurrent Rhabdomyosarcoma; Recurrent Soft Tissue Sarcoma; Recurrent Thyroid Gland Medullary Carcinoma; Refractory Ewing Sarcoma; Refractory Malignant Central Nervous System Neoplasm; Refractory Malignant Solid Neoplasm; Refractory Osteosarcoma; Refractory Rhabdomyosarcoma; Refractory Soft Tissue Sarcoma; Renal Cell Carcinoma; Rhabdomyosarcoma; Solid Neoplasm; Thyroid Gland Medullary Carcinoma; Wilms Tumor
Interventions: Drug: Cabozantinib; Drug: Cabozantinib S-malate; Other: Pharmacological Study
Sponsor: National Cancer Institute (NCI)
Recruiting
Nivolumab and Ipilimumab in Treating Patients With Rare Tumors

Posted: July 15th, 2016, 2:00pm GMT

Conditions: Acinar Cell Carcinoma; Adenoid Cystic Carcinoma; Adrenal Cortex Carcinoma; Adrenal Gland Pheochromocytoma; Anal Canal Neuroendocrine Carcinoma; Anal Canal Undifferentiated Carcinoma; Angiosarcoma; Apocrine Neoplasm; Appendix Mucinous Adenocarcinoma; Bartholin Gland Transitional Cell Carcinoma; Basal Cell Carcinoma; Bladder Adenocarcinoma; Cervical Adenocarcinoma; Cervical Clear Cell Adenocarcinoma; Cholangiocarcinoma; Chordoma; Colorectal Squamous Cell Carcinoma; Desmoid-Type Fibromatosis; Endometrial Transitional Cell Carcinoma; Endometrioid Adenocarcinoma; Esophageal Neuroendocrine Carcinoma; Esophageal Undifferentiated Carcinoma; Extrahepatic Bile Duct Carcinoma; Extramammary Paget Disease; Fallopian Tube Adenocarcinoma; Fallopian Tube Transitional Cell Carcinoma; Fibromyxoid Tumor; Gallbladder Carcinoma; Gastric Neuroendocrine Carcinoma; Gastric Squamous Cell Carcinoma; Gastric Undifferentiated Carcinoma; Gastrointestinal Stromal Tumor; Gestational Trophoblastic Tumor; Giant Cell Carcinoma; Intestinal Neuroendocrine Carcinoma; Intrahepatic Cholangiocarcinoma; Lung Carcinoid Tumor; Lung Sarcomatoid Carcinoma; Major Salivary Gland Carcinoma; Malignant Odontogenic Neoplasm; Malignant Peripheral Nerve Sheath Tumor; Malignant Testicular Sex Cord-Stromal Tumor; Metaplastic Breast Carcinoma; Metastatic Malignant Neoplasm of Unknown Primary; Minimally Invasive Lung Adenocarcinoma; Mixed Mesodermal (Mullerian) Tumor; Mucinous Adenocarcinoma; Mucinous Cystadenocarcinoma; Nasal Cavity Adenocarcinoma; Nasal Cavity Carcinoma; Nasopharyngeal Carcinoma; Nasopharyngeal Papillary Adenocarcinoma; Nasopharyngeal Undifferentiated Carcinoma; Oral Cavity Carcinoma; Oropharyngeal Undifferentiated Carcinoma; Ovarian Adenocarcinoma; Ovarian Clear Cell Adenocarcinoma; Ovarian Germ Cell Tumor; Ovarian Mucinous Adenocarcinoma; Ovarian Squamous Cell Carcinoma; Ovarian Transitional Cell Carcinoma; Pancreatic Acinar Cell Carcinoma; Pancreatic Neuroendocrine Carcinoma; Paraganglioma; Paranasal Sinus Adenocarcinoma; Paranasal Sinus Carcinoma; Parathyroid Gland Carcinoma; PEComa; Peritoneal Mesothelioma; Pituitary Gland Carcinoma; Placental Choriocarcinoma; Primary Peritoneal High Grade Serous Adenocarcinoma; Pseudomyxoma Peritonei; Rare Disorder; Scrotal Squamous Cell Carcinoma; Seminal Vesicle Adenocarcinoma; Seminoma; Serous Cystadenocarcinoma; Small Intestinal Adenocarcinoma; Small Intestinal Squamous Cell Carcinoma; Solid Neoplasm; Spindle Cell Neoplasm; Squamous Cell Carcinoma of the Penis; Teratoma With Somatic-Type Malignancy; Testicular Non-Seminomatous Germ Cell Tumor; Thyroid Gland Carcinoma; Tracheal Carcinoma; Transitional Cell Carcinoma; Ureter Adenocarcinoma; Ureter Squamous Cell Carcinoma; Urethral Adenocarcinoma; Urethral Squamous Cell Carcinoma; Vaginal Adenocarcinoma; Vaginal Squamous Cell Carcinoma, Not Otherwise Specified; Vulvar Carcinoma
Interventions: Procedure: Biospecimen Collection; Biological: Ipilimumab; Biological: Nivolumab
Sponsor: National Cancer Institute (NCI)
Recruiting
$Permalink for 'Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)'$
Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)

Posted: June 8th, 2015, 2:00pm GMT

Conditions: Advanced Malignant Solid Neoplasm; Bladder Carcinoma; Breast Carcinoma; Cervical Carcinoma; Colon Carcinoma; Colorectal Carcinoma; Endometrial Carcinoma; Esophageal Carcinoma; Gastric Carcinoma; Glioma; Head and Neck Carcinoma; Kidney Carcinoma; Liver and Intrahepatic Bile Duct Carcinoma; Lung Carcinoma; Lymphoma; Malignant Uterine Neoplasm; Melanoma; Ovarian Carcinoma; Pancreatic Carcinoma; Plasma Cell Myeloma; Prostate Carcinoma; Rectal Carcinoma; Recurrent Bladder Carcinoma; Recurrent Breast Carcinoma; Recurrent Cervical Carcinoma; Recurrent Colon Carcinoma; Recurrent Colorectal Carcinoma; Recurrent Esophageal Carcinoma; Recurrent Gastric Carcinoma; Recurrent Glioma; Recurrent Head and Neck Carcinoma; Recurrent Liver Carcinoma; Recurrent Lung Carcinoma; Recurrent Lymphoma; Recurrent Malignant Solid Neoplasm; Recurrent Melanoma; Recurrent Ovarian Carcinoma; Recurrent Pancreatic Carcinoma; Recurrent Plasma Cell Myeloma; Recurrent Prostate Carcinoma; Recurrent Rectal Carcinoma; Recurrent Skin Carcinoma; Recurrent Thyroid Gland Carcinoma; Recurrent Uterine Corpus Carcinoma; Refractory Lymphoma; Refractory Malignant Solid Neoplasm; Refractory Plasma Cell Myeloma; Skin Carcinoma; Thyroid Gland Carcinoma; Uterine Corpus Cancer
Interventions: Drug: Adavosertib; Drug: Afatinib; Drug: Afatinib Dimaleate; Drug: Binimetinib; Drug: Capivasertib; Drug: Copanlisib; Drug: Copanlisib Hydrochloride; Drug: Crizotinib; Other: Cytology Specimen Collection Procedure; Drug: Dabrafenib; Drug: Dabrafenib Mesylate; Drug: Dasatinib; Drug: Defactinib; Drug: Defactinib Hydrochloride; Drug: Erdafitinib; Drug: FGFR Inhibitor AZD4547; Drug: Ipatasertib; Other: Laboratory Biomarker Analysis; Drug: Larotrectinib; Drug: Larotrectinib Sulfate; Biological: Nivolumab; Drug: Osimertinib; Drug: Palbociclib; Biological: Pertuzumab; Drug: PI3K-beta Inhibitor GSK2636771; Drug: Sapanisertib; Drug: Sunitinib Malate; Drug: Taselisib; Drug: Trametinib; Biological: Trastuzumab; Biological: Trastuzumab Emtansine; Drug: Ulixertinib; Drug: Vismodegib
Sponsor: National Cancer Institute (NCI)
Recruiting
Exercise Intervention for LGBT Cancer Survivors

Posted: June 2nd, 2015, 2:00pm GMT

Condition: Neoplasms
Intervention: Behavioral: Exercise for Cancer Patients
Sponsor: University of Rochester
Recruiting
Natural History Study of Children and Adults With Medullary Thyroid Cancer

Posted: August 9th, 2012, 2:00pm GMT

Condition: Medullary Thyroid Carcer
Intervention:
Sponsor: National Cancer Institute (NCI)
Recruiting
Prospective Comprehensive Molecular Analysis of Endocrine Neoplasms

Posted: November 2nd, 2009, 3:00pm GMT

Conditions: Endocrine Tumors; Thyroid Neoplasms; Parathyroid Neoplasms; Adrenal Neoplasm; Neuroblastoma
Intervention:
Sponsor: National Cancer Institute (NCI)
Recruiting
Study of Adrenal Gland Tumors

Posted: June 29th, 2000, 2:00pm GMT

Condition: Adrenal Gland Neoplasm
Intervention:
Sponsor: Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
Recruiting
Diagnosis of Pheochromocytoma

Posted: March 3rd, 2000, 3:00pm GMT

Conditions: Pheochromocytoma; Endocrine Disease; Endocrine Diseases
Interventions: Drug: ([18F]-DOPA); Drug: [68Ga]-DOTATATE; Drug: Romidepsin; Drug: ([18F]-6F-DA)
Sponsor: Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
Recruiting
Defining the Genetic Basis for the Development of Primary Pigmented Nodular Adrenocortical Disease (PPNAD) and the Carney Complex

Posted: November 4th, 1999, 3:00pm GMT

Conditions: Cushing's Syndrome; Pituitary Adenoma; Carney Complex; Primary Pigmented Nodular Adrenocortical Disease; Peutz-Jeghers Syndrome
Intervention:
Sponsor: Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
Recruiting

← PubMed - Adrenocortical Carcinoma Trial - Adrenocortical Carcinoma →

Rare Cancer News & Clinical Trials » Trial - Adrenal Cancer

Feeds

Trial - Adrenal Cancer (26 unread)

Posted: January 13th, 2020, 3:00pm GMT

Posted: January 8th, 2020, 3:00pm GMT

Posted: December 12th, 2019, 3:00pm GMT

Posted: December 10th, 2019, 3:00pm GMT

Posted: December 6th, 2019, 3:00pm GMT

Posted: December 5th, 2019, 3:00pm GMT

Posted: July 25th, 2019, 2:00pm GMT

Posted: July 15th, 2019, 2:00pm GMT

Posted: January 10th, 2019, 3:00pm GMT

Posted: December 18th, 2018, 3:00pm GMT

Posted: April 3rd, 2018, 2:00pm GMT

Posted: December 15th, 2017, 3:00pm GMT

Posted: September 13th, 2017, 2:00pm GMT

Posted: July 13th, 2017, 2:00pm GMT

Posted: July 2nd, 2017, 2:00pm GMT

Posted: May 24th, 2017, 2:00pm GMT

Posted: February 16th, 2017, 3:00pm GMT

Posted: August 16th, 2016, 2:00pm GMT

Posted: July 15th, 2016, 2:00pm GMT

Posted: June 8th, 2015, 2:00pm GMT

Posted: June 2nd, 2015, 2:00pm GMT

Posted: August 9th, 2012, 2:00pm GMT

Posted: November 2nd, 2009, 3:00pm GMT

Posted: June 29th, 2000, 2:00pm GMT

Posted: March 3rd, 2000, 3:00pm GMT

Posted: November 4th, 1999, 3:00pm GMT